Navigation Links
Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
Date:3/6/2012

Bethesda, MDA new research discovery by a team of Stanford and European scientists offers hope that people with atherosclerotic disease may one day be able to avoid limb amputation related to ischemia. A new research report appearing online in the FASEB Journal suggests that the delivery of genes for two molecules naturally produced by the body, called "PDGF-BB" and "VEGF" may successfully cause the body to grow new blood vessels that can save ischemic limbs.

"We hope that our findings will ultimately develop into a safe and effective therapy for the many patients, suffering from blocked arteries in the limbs, who are currently not adequately treated by surgery or drugs," said Helen M. Blau, Ph.D., a senior researcher involved in the work and Associate Editor of the FASEB Journal from the Baxter Laboratory for Stem Cell Biology at the Institute for Regenerative Medicine and Stem Cell Biology at Stanford. "This could help avoid the devastating consequences of limb amputations for both patients and their families."

To make this discovery, Blau and colleagues, including Andrea Banfi (now at Basel University), introduced the genes for PDGF-BB and VEGF into the muscles of mice, either independently or together. When high doses of VEGF alone were produced, they caused the growth of vascular tumors. When the two factors were produced in unbalanced amounts, tumor growth also occurred. When VEGF and PDGF were delivered in a fixed ratio relative to one another, however, no tumors occurred, and blood flow was restored to ischemic muscle tissue and damage repaired without any toxic effects. To achieve a "balanced" delivery of PDGF-BB and VEGF, scientists placed both genes in a single gene therapy delivery mechanism, called a "vector."

Although the report shows the feasibility of growing robust and safe new blood vessels that restore blood flow to diseased tissues, Blau points out that "there are multiple challenges to correcting peripheral vasculature disease by using proangiogenic gene therapy strategies. Two important challenges are what to deliver and how to get it to where it can have beneficial effects. Clinical success will require both delivering a gene therapy construct that encodes for effective angiogenic factors and ensuring that the sites of delivery are where the construct can have the greatest clinical benefit."

"This ingenious work, based on the latest techniques of molecular biology, tells us that it is possible to reinvigorate parts of our body that can't get enough blood to keep them going," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "The next question is whether this approach will work in humans and exactly how to deliver the new treatment to places that need it the most."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Stanford scientist to discuss the challenges and opportunities of carbon sequestration at AAAS
2. JoVE partners with Stanford University for Medicine X Conference
3. AGU meeting: Stanford scientists subject rocks to hellish conditions to combat global warming
4. Squid mystery in Mexican waters unraveled by Stanford biologist and a class of students
5. OpenSim open-source software from Stanford accurately models human motion
6. Gene variation predicts rate of age-related decline in mental performance, Stanford study
7. Stanford researchers examine impact of green politics on recent national elections
8. Stanford Precourt Institute and TomKat Center award energy research grants
9. Dual-action protein developed at Stanford better restricts blood vessel formation
10. Stanford engineers redefine how the brain plans movement
11. Global warming could alter the US premium wine industry in 30 years, says Stanford study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):
(Date:5/24/2017)... ... May 24, 2017 , ... Today, ... CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery (ABNR™) technology at its 4,000,000 gallon ... million plant upgrade to sustainably meet current and future nutrient discharge regulations. The ...
(Date:5/23/2017)... ... May 23, 2017 , ... Firmex today announced ... it easy for organizations to send and gather large files and confidential documents ... email file size limitations. , Using the same market-tested infrastructure as Firmex’s ...
(Date:5/23/2017)... , ... May 22, 2017 , ... ... Photonics 2017 in San Diego, California, this August will feature high-level speakers ... and autonomous vehicles. , SPIE Optics and Photonics, the largest multidisciplinary optical sciences ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge Semantics , the leading provider of ... Bio-IT World Conference and Expo in Boston May 23-25 with a featured speaker ... Anzo Smart Data Lake is also a finalist for the Best of Show award. ...
Breaking Biology Technology: